Every 8-K that Jasper Therapeutics, Inc. (JSPR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow JSPR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full JSPR filings page.
Jasper Therapeutics, Inc. (JSPR) reports that on August 21, 2026 it received a Nasdaq notice that, based on stockholders’ equity reported in its June 30, 2026 Form 10-Q, it no longer meets the $2,500,000 minimum stockholders’ equity requirement for listing on The Nasdaq Capital Market under Rule 5550(b)(1).
The notice has no immediate effect on trading while Jasper remains in compliance with other continued listing standards. The company has 45 days, until October 5, 2026, to submit a compliance plan and may receive up to 180 days from August 21, 2026 to regain compliance if Nasdaq accepts the plan. Jasper currently anticipates seeking stockholder approval to convert outstanding Non-Voting Convertible Preferred Stock at a special stockholder meeting as part of regaining compliance, but states there is no assurance that approvals will be obtained, that Nasdaq will accept its plan, or that it will ultimately maintain its Nasdaq listing.
Jasper Therapeutics reported much lower losses for the quarter ended June 30, 2026 and detailed major strategic steps. For the quarter, operating expenses were about $9.2 million, including research and development of roughly $5.1 million and general and administrative costs of about $4.1 million. Net loss was approximately $2.8 million, compared with $26.7 million in the same quarter of 2025, helped by $6.4 million of total other income, including changes in warrant liability.
As of June 30, 2026, Jasper had $7.3 million in cash and cash equivalents and total assets of about $11.8 million, with stockholders’ equity of $1.4 million. After quarter-end, Jasper closed the acquisition of Kira Pharmaceuticals and completed a concurrent $132 million PIPE financing. Management states that, supported by this financing, it believes it has sufficient capital to fund planned operations through the second half of 2028 while advancing its clinical pipeline, including KP-104, briquilimab, and KP-701.
Jasper Therapeutics, Inc. reported voting results from its 2026 Annual Meeting of Stockholders held on July 31, 2026. A total of 21,121,396 shares of voting common stock, or approximately 75% of the 28,009,802 shares outstanding as of June 5, 2026, were represented virtually or by proxy.
For the election of two Class II directors, stockholders cast 9,273,875 votes for and 419,763 withheld for Judith Shizuru, M.D., Ph.D., and 9,280,610 votes for and 413,028 withheld for Tom Wiggans, with 11,427,758 broker non-votes for each nominee. On the proposal to ratify PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, votes totaled 20,635,404 for, 434,262 against, and 51,730 abstentions. On the advisory vote regarding compensation of named executive officers, stockholders cast 9,016,797 votes for, 604,173 against, 72,668 abstentions, and 11,427,758 broker non-votes.
Jasper Therapeutics, Inc. describes contingent value rights granted in connection with its acquisition of Kira Pharmaceuticals. Each holder of voting common stock of Jasper of record immediately before the merger’s Effective Time is entitled to one contractual contingent value right (CVR) per share.
Each CVR gives the holder a pro rata portion of a $30.0 million Milestone Payment if the U.S. Food and Drug Administration issues a Priority Review Voucher for briquilimab on or before December 31, 2028. Payment timing depends on any Change of Control and a Monetization Event, with payment generally due within 90 days after monetization. The CVRs are generally non-transferable, not certificated, and not registered or listed. The record date for CVR eligibility was July 16, 2026, the closing date of the Kira acquisition.
Jasper Therapeutics completed an all-stock acquisition of Kira Pharmaceuticals, making Kira a wholly owned subsidiary. At closing Jasper issued 5,195,009 shares of common stock and 4,644,977 shares of non-voting convertible preferred stock, each preferred share being convertible into 61 common shares, and assumed Kira options and SAFEs. Immediately after the merger and before new financing, former Kira equityholders held about 88.73% of fully diluted common stock and pre-transaction Jasper holders about 11.27%.
Jasper also agreed to a $132 million private placement of roughly 4.7 million preferred shares, after which pre-transaction Jasper holders, former Kira holders and PIPE investors are expected to own 6.68%, 49.86% and 43.46% of fully diluted common stock, assuming full conversion. Legacy Jasper shareholders receive one non-transferable contingent value right per share, tied to a potential $30 million payment if the FDA grants a Priority Review Voucher for briquilimab by December 31, 2028. Kira licensed KP-301 and KP-402 to Mirador Therapeutics for $12 million upfront, up to $108.5 million in development and regulatory milestones, up to $350 million in sales milestones and tiered royalties. Jasper created a new preferred class with protective voting rights, automatic conversion after stockholder approval and beneficial ownership caps, and refreshed leadership by adding director Patrick Crutcher and appointing Matthew Ros as chief operating officer.
Jasper Therapeutics completed an all-stock acquisition of Kira Pharmaceuticals, combining their immunology-focused pipelines into a single company that will continue trading on Nasdaq under the ticker JSPR. Kira contributed complement-therapy assets including KP-104 and KP-701, while Jasper adds briquilimab, an anti-KIT monoclonal antibody.
Alongside the merger, Jasper agreed to sell approximately 4.7 million shares of non-voting convertible preferred stock in a private placement for gross proceeds of about $132 million, with each preferred share convertible into 61 common shares, subject to stockholder approval and beneficial ownership limits. Kira out-licensed KP-301 and KP-402 to Mirador Therapeutics for $12 million upfront plus potential milestones. Pro forma ownership is expected to be 6.68% for pre-transaction Jasper holders, 49.86% for former Kira equityholders and 43.46% for private placement investors, with about 653.6 million common shares outstanding. Available cash, including the financing and out-licensing proceeds, is expected to fund operations through the second half of 2028 and support multiple clinical milestones.
Jasper Therapeutics reported receiving a Nasdaq notice that its voting common stock failed to meet the $1.00-per-share minimum bid requirement for the last thirty consecutive business days under Nasdaq Listing Rule 5550(a)(2). Nasdaq has given the company 180 calendar days, until November 30, 2026, to regain compliance by having its stock close at or above $1.00 for at least ten consecutive business days.
The notice does not immediately affect trading, and the stock and public warrants continue on the Nasdaq Capital Market under “JSPR” and “JSPRW.” If compliance is not restored, Jasper may qualify for an additional 180-day period and is evaluating options, including a potential reverse stock split, but there is no assurance it will meet Nasdaq’s standards.
Jasper Therapeutics, Inc. announced that its Board has begun a comprehensive review of strategic alternatives following an evaluation of current market conditions, with the stated goal of maximizing shareholder value.
Options under consideration include a sale or licensing of assets, collaborations, a sale of the company, a merger or other strategic transaction, or an orderly wind-down of operations. The company plans to keep evaluating cost‑saving measures to preserve cash and to maintain compliance with regulatory and financial reporting requirements. There is no defined timeline for the process, and Jasper does not guarantee that any transaction will be announced or completed.
Jasper Therapeutics, Inc. reported a governance change as director Christian Nolet resigned from the Board of Directors and the Board committees on which he served, effective May 15, 2026. The company stated that his resignation was not due to any disagreement regarding its operations, policies, or practices.
The Board appointed Svetlana Lucas, Ph.D. as a member of the Board’s Audit Committee. The filing also reiterates that Jasper’s voting common stock, with a par value of $0.0001 per share, trades on Nasdaq under the symbol JSPR, and its redeemable warrants trade under JSPRW.
Jasper Therapeutics reported first quarter 2026 results and a corporate update centered on its briquilimab program for mast cell diseases such as chronic spontaneous urticaria. The company recorded a net loss of $1,174 thousand for the quarter, significantly lower than $21,241 thousand a year earlier, as research and development expenses fell to $5,814 thousand from $16,157 thousand and general and administrative costs edged down to $5,138 thousand from $5,645 thousand.
Total operating expenses were $10,952 thousand, offset in part by $9,640 thousand of non-cash income from a change in fair value of warrant liability, which contributed to the smaller loss. Cash and cash equivalents were $14,144 thousand as of March 31, 2026, down from $28,692 thousand at December 31, 2025. Jasper is refining its Phase 2b briquilimab trial design in CSU, plans to start the study in the second half of the year, and explicitly notes an imminent need to raise additional funding and risks to its ability to continue as a going concern and to execute the Phase 2b/3 program.
Jasper Therapeutics reported its fourth quarter and full-year 2025 results and provided a corporate update focused on briquilimab, its antibody therapy for mast cell–driven diseases such as chronic urticaria and asthma. For 2025, operating expenses were $83.9 million, driven by $63.1 million in research and development and $20.8 million in general and administrative costs. Net loss for 2025 was $75.8 million compared with $71.3 million in 2024, reflecting continued investment in clinical programs. As of December 31, 2025, Jasper held $28.7 million in cash and cash equivalents, down from $71.6 million a year earlier, and reported total assets of $35.8 million and stockholders’ equity of $4.2 million. The company plans to begin enrolling patients in the Phase 2b portion of a planned Phase 2b/3 chronic spontaneous urticaria study in the second half of 2026, pending capital availability.
Jasper Therapeutics, Inc. reported that it has released a press release with positive updated clinical data from its BEACON Phase 1b/2a study of subcutaneous briquilimab in adult participants with chronic spontaneous urticaria, along with data from an open-label extension study in chronic spontaneous and chronic inducible urticaria. The company is also hosting a conference call and webinar at 8:00 a.m. Eastern Time on January 8, 2026 to present these updated BEACON and open-label extension results. The press release and the related investor presentation are provided as exhibits to this report.
Jasper Therapeutics reported leadership changes, with the Board determining that, effective January 5, 2026, Ron Martell would cease serving as Chief Executive Officer and President. Under his amended employment agreement, this termination is treated as without cause, and he is eligible for 18 months of base salary and up to 18 months of COBRA premium payments, subject to signing a release in favor of the company.
Effective the same date, the Board appointed current Chief Operating Officer Jeet Mahal as Chief Executive Officer and President and as a Class III director, making him the company’s principal executive officer. His annualized salary was increased to $600,000, and he is eligible for an annual performance bonus of up to 50% of base salary, with future compensation adjustments at the Compensation Committee’s discretion. The Board also named current Chairperson Thomas G. Wiggans as Executive Chair, further formalizing his leadership role.
Jasper Therapeutics (JSPR) furnished an 8-K announcing it issued a press release reporting financial results for the quarter ended September 30, 2025, along with a corporate update.
The release is attached as Exhibit 99.1 and was furnished under Item 2.02 and Item 9.01. The company notes this information is being furnished and not deemed filed under Section 18 of the Exchange Act or incorporated by reference, except as expressly set forth.
Jasper Therapeutics, Inc. filed an 8-K reporting a material event that includes an Underwriting Agreement dated September 18, 2025 with TD Securities (USA) LLC and a set of exhibits: forms of pre-funded and common warrants, a legal opinion and consent from Paul Hastings LLP, a press release dated September 18, 2025, and an iXBRL cover page file. The filing also describes a comprehensive review and testing program for manufacturing and clinical supply lots, including robust lot testing, independent blinded testing of returned product samples, stability comparisons, and reviews of patient selection, investigational product handling, and drug delivery details. The form is signed by CFO Herb Cross on September 19, 2025. No offering terms, proceeds, or financial impacts are disclosed in the provided text.
Jasper Therapeutics, Inc. furnished an 8-K to share that it issued a press release on August 13, 2025 reporting its financial results for the quarter ended June 30, 2025 and providing a corporate update. The press release is attached as Exhibit 99.1, and the company notes that this information is furnished, not filed, so it is not subject to certain Exchange Act liabilities and is not automatically incorporated into other securities filings unless specifically referenced.
Jasper Therapeutics, Inc. (Nasdaq: JSPR) filed a Form 8-K dated July 7, 2025 to disclose a material corporate event under Item 8.01.
The company issued a press release (Exhibit 99.1) announcing updated data from its BEACON Phase 1b/2a study evaluating subcutaneous briquilimab in adults with chronic spontaneous urticaria. Jasper will host a conference call and webinar on July 7, 2025 at 8:30 a.m. EDT to discuss the new findings and provide a program update. A supporting investor presentation is furnished as Exhibit 99.2. No financial statements or earnings figures accompany this filing.
Key administrative details include the trading symbols JSPR (common stock) and JSPRW (warrants), and confirmation of listing on The Nasdaq Stock Market LLC. The filing contains customary signatures and an iXBRL cover page file (Exhibit 104).